Intestinal FXR is activated in high-fat-fed mice and the use of intestinal FXR inhibitors could reduce ceramide production and control hypercholesterolemia, leading to new directions in the treatment of atherosclerosis (Wu et al., 2021). This evidence concerns the gene NR1H4 and familial hypercholesterolemia.